

January 24, 2023

Q3FY23 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

Change in Estimates

	Cur	rent	Prev	vious
	FY24E	FY25E	FY24E	FY25E
Rating	Н	OLD	Н	OLD
Target Price	1,	578	1,	639
Sales (Rs. m)	56,323	60,720	56,892	61,783
% Chng.	(1.0)	(1.7)		
EBITDA (Rs. m)	16,485	18,208	16,702	18,505
% Chng.	(1.3)	(1.6)		
EPS (Rs.)	41.6	46.4	42.2	46.4
% Chng.	(1.4)	0.1		

Key Financials - Standalone

Y/e Mar	FY22	FY23E	FY24E	FY25E
Sales (Rs. m)	50,998	52,345	56,323	60,720
EBITDA (Rs. m)	15,659	15,125	16,485	18,208
Margin (%)	30.7	28.9	29.3	30.0
PAT (Rs. m)	10,783	10,277	11,309	12,623
EPS (Rs.)	39.6	37.8	41.6	46.4
Gr. (%)	4.1	(4.7)	10.0	11.6
DPS (Rs.)	40.0	36.0	38.0	42.0
Yield (%)	2.7	2.5	2.6	2.9
RoE (%)	74.4	58.4	61.7	65.1
RoCE (%)	95.8	75.9	79.7	83.9
EV/Sales (x)	7.6	7.4	6.9	6.3
EV/EBITDA (x)	24.9	25.6	23.4	21.1
PE (x)	36.8	38.6	35.1	31.4
P/BV (x)	22.9	22.3	21.1	19.9

Key Data	COLG.BO CLGT IN
52-W High / Low	Rs.1,696 / Rs.1,376
Sensex / Nifty	60,979 / 18,118
Market Cap	Rs.397bn/ \$ 4,857m
Shares Outstanding	272m
3M Avg. Daily Value	Rs.567.03m

Shareholding Pattern (%)

Promoter's	51.00
Foreign	21.11
Domestic Institution	7.83
Public & Others	20.06
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(6.9)	(9.1)	3.9
Relative	(8.6)	(16.4)	(2.0)

Amnish Aggarwal

amnishaggarwal@plindia.com | 91-22-66322233

Harish Advani

harishadvani@plindia.com | 91-22-66322242

Anushka Chhajed

anushkachhajed@plindia.com | 91-22-66322244

Colgate Palmolive (CLGT IN)

Rating: HOLD | CMP: Rs1,459 | TP: Rs1,578

Volume decline across both urban and rural

Quick Pointers:

- Volume decline by ~3%, demand under pressure across rural/urban, outlook cautiously optimistic
- Raw material trends flattish, 3% price increase in 3Q.
- Premium segment doing better than Colgate Strong Teeth and Herbal

We cut FY23/24/FY25 EPS by 0.6%/1.4%/0.1% factoring 1) lower volume growth given tepid demand, 2) increase in ad spends, promotional intensity and 3) higher tax rates in FY23/24. CLGT reported tepid numbers with 3% decline in volumes and sustained competitive activity in core category of oral care. Demand trends remain tepid with even urban demand declining QoQ. We believe margins have bottomed out given flattish RM trends and benefits of ~3% price hike in the portfolio.

Colgate remains focused on low growth oral care segment across price points, which we believe will curtail overall growth. We see limited focus on high growth personal care which has much higher penetration opportunities. We estimate 7.7% Sales and 10.6% PAT CAGR over FY23-25 assuming 4.7% decline in FY23 EPS. Revival in rural demand and new launches in personal care hold key to valuations. Although CLGT's growth is unexciting, favourable financial parameters (2.5% Dividend yield, 90%+ payout and ~80% ROCE) limit downside. We value CLGT at 35x Dec'24 EPS and assign a Target of Rs 1578 (earlier Rs 1639 on 37xSep'24 EPS). Hold.

Sales grew 0.9%, EBITDA Margins contracted by 174bps: Revenues grew by 0.9% YoY to Rs12.9bn (PLe: Rs13.2bn), we estimate volume decline of 3%. Gross margins contracted by 73bps YoY to 65.9% (Ple: 64.0%). EBITDA declined by 5% YoY to Rs3.6bn (PLe:Rs3.8bn); Margins contracted by 174bps YoY to 28% (PLe:28.8%). A&P spends expanded by 137bps YoY to 13.2%. Adj. PAT declined by 3.6% YoY to Rs2.4bn (PLe:Rs2.6bn)

Key Highlights:

- Toothpaste volumes under pressure across rural and urban India,
- Premium segment doing better, Colgate Strong Teeth and Herbal under pressure, CLGT increasing advertising and promotions in tough market
- Body wash growing steadily while Handwash demand volatile
- Launched e-comm platform exclusively for dentists dentistfirst.co.in
- CLGT continues to drive premiumisation across categories led by the MT & e-comm channels

January 24, 2023




Exhibit 1: 3QFY23: Net sales up 0.9%, EBITDA margins declined by 174bps

Y/e March	3QFY23	3QFY22	YoY gr. (%)	2QFY23	9MFY23	9MFY22	YoY gr. (%)
Net Sales	12,913	12,801	0.9	13,875	38,756	37,985	2.0
Gross Profit	8,506	8,526	(0.2)	8,846	25,289	25,626	(1.3)
Margin %	65.9	66.6	(0.7)	63.8	65.3	67.5	(2.2)
Other Exp	4891	4720	3.6	4766	14338	14261	0.5
% of Net sales	37.9	36.9		34.3	37.0	37.5	
EBITDA	3,615	3,806	(5.0)	4,080	10,951	11,365	(3.6)
Margin %	28.0	29.7	(1.7)	29.4	28.3	29.9	(1.7)
Depreciation	437	439	(0.6)	439	1317	1335	(1.4)
Interest	13	15		13	38	46	
PBT from operations	3165	3351	(5.6)	3629	9596	9985	(3.9)
Other Income	104	57	83.3	113	332	174	91.0
PBT	3,269	3,408	(4.1)	3,741	9,928	10,159	(2.3)
Tax	837	885	(5.4)	961	2526	2611	(3.3)
Tax rate %	25.6	26.0		25.7	25.4	25.7	
Adj. PAT	2,432	2,523	(3.6)	2,780	7,403	7,547	(1.9)

Source: Company, PL

Exhibit 2: Toothpaste volumes decline 3%



Source: Company, PL



Financials

Income Statement ((Rs m)	į
--------------------	--------	---

Y/e Mar	FY22	FY23E	FY24E	FY25E
Net Revenues	50,998	52,345	56,323	60,720
YoY gr. (%)	5.3	2.6	7.6	7.8
Cost of Goods Sold	16,675	18,095	19,138	20,334
Gross Profit	34,323	34,250	37,185	40,386
Margin (%)	67.3	65.4	66.0	66.5
Employee Cost	3,851	3,900	4,197	4,465
Other Expenses	4,146	4,241	4,564	4,921
EBITDA	15,659	15,125	16,485	18,208
YoY gr. (%)	3.7	(3.4)	9.0	10.5
Margin (%)	30.7	28.9	29.3	30.0
Depreciation and Amortization	1,773	1,772	1,877	1,953
EBIT	13,886	13,353	14,608	16,255
Margin (%)	27.2	25.5	25.9	26.8
Net Interest	59	62	66	56
Other Income	263	448	578	676
Profit Before Tax	14,090	13,740	15,119	16,875
Margin (%)	27.6	26.2	26.8	27.8
Total Tax	3,307	3,462	3,810	4,253
Effective tax rate (%)	23.5	25.2	25.2	25.2
Profit after tax	10,783	10,277	11,309	12,623
Minority interest	=	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	10,783	10,277	11,309	12,623
YoY gr. (%)	4.1	(4.7)	10.0	11.6
Margin (%)	21.1	19.6	20.1	20.8
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	10,783	10,277	11,309	12,623
YoY gr. (%)	4.1	(4.7)	10.0	11.6
Margin (%)	21.1	19.6	20.1	20.8
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	10,783	10,277	11,309	12,623
Equity Shares O/s (m)	272	272	272	272
EPS (Rs)	39.6	37.8	41.6	46.4

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Balance Sheet Abstract (Rs	m)			
Y/e Mar	FY22	FY23E	FY24E	FY25E
Non-Current Assets				
Gross Block	18,177	18,177	19,045	19,745
Tangibles	18,177	18,177	19,045	19,745
Intangibles	-	-	-	-
Acc: Dep / Amortization	10,159	11,686	13,305	14,983
Tangibles	10,159	11,686	13,305	14,983
Intangibles	-	-	-	-
Net fixed assets	8,018	6,491	5,741	4,762
Tangibles	8,018	6,491	5,741	4,762
Intangibles	-	-	-	-
Capital Work In Progress	1,218	1,100	1,150	1,200
Goodwill	-	-	-	-
Non-Current Investments	184	193	202	211
Net Deferred tax assets	173	-	-	-
Other Non-Current Assets	4,597	4,560	4,528	4,498
Current Assets				
Investments	7,082	7,799	8,953	9,654
Inventories	3,572	4,061	4,216	4,406
Trade receivables	2,247	2,279	2,453	2,645
Cash & Bank Balance	466	1,344	2,095	3,742
Other Current Assets	319	520	560	603
Total Assets	29,018	29,554	31,164	33,050
Equity				
Equity Share Capital	272	272	272	272
Other Equity	17,075	17,560	18,534	19,689
Total Networth	17,347	17,832	18,806	19,961
Non-Current Liabilities				
Long Term borrowings	-	-	-	-
Provisions	140	195	210	223
Other non current liabilities	695	527	367	230
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	7,714	7,835	8,432	9,092
Other current liabilities	3,111	3,152	3,335	3,530
Total Equity & Liabilities	29,018	29,554	31,164	33,050

Source: Company Data, PL Research



Cash Flow (Rs m)				
Y/e Mar	FY22	FY23E	FY24E	FY25E
PBT	14,090	13,740	15,119	16,875
Add. Depreciation	1,773	1,772	1,877	1,953
Add. Interest	59	62	66	56
Less Financial Other Income	263	448	578	676
Add. Other	-	-	-	-
Op. profit before WC changes	15,922	15,573	17,063	18,884
Net Changes-WC	(12,473)	(1,323)	(994)	(510)
Direct tax	(3,307)	(3,462)	(3,810)	(4,297)
Net cash from Op. activities	142	10,788	12,258	14,077
Capital expenditures	(526)	(56)	(1,106)	(952)
Interest / Dividend Income	-	-	-	-
Others	186	-	-	-
Net Cash from Invt. activities	(339)	(56)	(1,106)	(952)
Issue of share cap. / premium	73	-	-	-
Debt changes	-	-	-	-
Dividend paid	(5,168)	(9,791)	(10,335)	(11,423)
Interest paid	(59)	(62)	(66)	(56)
Others	-	-	-	-
Net cash from Fin. activities	(5,154)	(9,853)	(10,402)	(11,479)
Net change in cash	(5,351)	879	751	1,646
Free Cash Flow	(383)	10,732	11,152	13,126

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q4FY22	Q1FY23	Q2FY23	Q3FY23
Net Revenue	13,013	11,968	13,875	12,913
YoY gr. (%)	1.4	2.6	2.6	0.9
Raw Material Expenses	4,317	4,031	5,029	4,407
Gross Profit	8,696	7,938	8,846	8,506
Margin (%)	66.8	66.3	63.8	65.9
EBITDA	4,294	3,257	4,080	3,615
YoY gr. (%)	1.8	(8.3)	1.8	(5.0)
Margin (%)	33.0	27.2	29.4	28.0
Depreciation / Depletion	438	442	439	437
EBIT	3,856	2,815	3,641	3,178
Margin (%)	29.6	23.5	26.2	24.6
Net Interest	14	13	13	13
Other Income	89	115	113	104
Profit before Tax	3,931	2,918	3,741	3,269
Margin (%)	30.2	24.4	27.0	25.3
Total Tax	1,015	727	961	837
Effective tax rate (%)	25.8	24.9	25.7	25.6
Profit after Tax	2,916	2,190	2,780	2,432
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	2,916	2,190	2,780	2,432
YoY gr. (%)	3.0	(6.1)	3.3	(3.6)
Margin (%)	22.4	18.3	20.0	18.8
Extra Ord. Income / (Exp)	320	(93)	-	-
Reported PAT	3,236	2,097	2,780	2,432
YoY gr. (%)	2.8	(10.1)	3.3	(3.6)
Margin (%)	24.9	17.5	20.0	18.8
Other Comprehensive Income	47	-	-	-
Total Comprehensive Income	3,282	2,097	2,780	2,432
Avg. Shares O/s (m)	272	272	272	272
EPS (Rs)	10.7	8.1	10.2	8.9


Source: Company Data, PL Research

Key Financial Metrics				
Y/e Mar	FY22	FY23E	FY24E	FY25E
Per Share(Rs)				
EPS	39.6	37.8	41.6	46.4
CEPS	46.2	44.3	48.5	53.6
BVPS	63.8	65.6	69.1	73.4
FCF	(1.4)	39.5	41.0	48.3
DPS	40.0	36.0	38.0	42.0
Return Ratio(%)				
RoCE	95.8	75.9	79.7	83.9
ROIC	152.8	118.3	150.3	203.1
RoE	74.4	58.4	61.7	65.1
Balance Sheet				
Net Debt : Equity (x)	(0.4)	(0.5)	(0.6)	(0.7)
Net Working Capital (Days)	(14)	(10)	(11)	(12)
Valuation(x)				
PER	36.8	38.6	35.1	31.4
P/B	22.9	22.3	21.1	19.9
P/CEPS	31.6	32.9	30.1	27.2
EV/EBITDA	24.9	25.6	23.4	21.1
EV/Sales	7.6	7.4	6.9	6.3
Dividend Yield (%)	2.7	2.5	2.6	2.9

Source: Company Data, PL Research

January 24, 2023





Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Asian Paints	Accumulate	3,150	2,866
2	Avenue Supermarts	BUY	4,675	3,864
3	Britannia Industries	Hold	4,297	4,359
4	Colgate Palmolive	Hold	1,639	1,517
5	Dabur India	Accumulate	609	553
6	Emami	Accumulate	521	420
7	Hindustan Unilever	Accumulate	2,800	2,650
8	ITC	Accumulate	365	335
9	Jubilant FoodWorks	BUY	610	504
10	Kansai Nerolac Paints	Accumulate	563	419
11	Marico	Hold	531	513
12	Mold-tek Packaging	Hold	940	983
13	Nestle India	Accumulate	20,201	19,890
14	Pidilite Industries	Hold	2,679	2,522
15	Restaurant Brands Asia	Accumulate	156	111
16	Titan Company	Accumulate	2,875	2,538
17	Westlife Foodworld	BUY	854	769

PL's Recommendation Nomenclature (Absolute Performance)

 Buy
 : > 15%

 Accumulate
 : 5% to 15%

 Hold
 : +5% to -5%

 Reduce
 : -5% to -15%

 Sell
 : < -15%</td>

Not Rated (NR) : No specific call on the stock
Under Review (UR) : Rating likely to change shortly



ANALYST CERTIFICATION

(Indian Clients)

We/l, Mr. Amnish Aggarwal- MBA, CFA, Mr. Harish Advani- PGDM Finance, Ms. Anushka Chhajed- CA Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Amnish Aggarwal- MBA, CFA, Mr. Harish Advani- PGDM Finance, Ms. Anushka Chhajed- CA Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com